TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03785756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 300 mg Oral Tablet
Description: 2 × 300 mg tablets at Hours 0 and 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg Oral Tablet
Description: 2 × 200 mg tablets at Hours 0, 8, and 16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of PR tablet
Description: 2 tablets up to four times in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of PR tablet
Description: 2 tablets up to four times in 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of PR tablet
Description: 2 tablets up to four times in 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of IR tablet
Description: 2 tablets up to four times in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of IR tablet
Description: 2 tablets up to four times in 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of IR tablet
Description: 2 tablets up to four times in 24 hours
Study: NCT03749811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
Study: NCT00193180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study: NCT01517464

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-94
Description: SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
Study: NCT01358058

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
Study: NCT01506999

Intervention type: BIOLOGICAL
Intervention: MULTIGENE SCREENING FOR SINGLE SNPS
Description: DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
Study: NCT02183779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-occlusive hyperemia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cooling box

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cooling box

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA and Fluconazole dermic injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA and Fluconazole dermic injection
Study: NCT02691325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA DPI
Description: Placebo ELLIPTA DPI contains lactose.
Study: NCT04150094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Description: Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training + intravaginal vibratory stimulus
Description: Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
Study: NCT00356343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES Strength Training
Description: Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volitional Strength Training
Description: Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
Study: NCT02014168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viroflu® and MVA-NP+M1
Description: 2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viroflu® and saline placebo
Description: 2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo.
Study: NCT02691325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA DPI
Description: Placebo ELLIPTA DPI contains lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA DPI
Description: Placebo ELLIPTA DPI contains lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA DPI
Description: Placebo ELLIPTA DPI contains lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
Study: NCT04172935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Presbyopic Glasses/ Intervention Group
Description: Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
Study: NCT02325492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03694834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics.
Study: NCT02407288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial dirrect current stimulation
Description: The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
Study: NCT03694834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy/Surgical Staging per institutional standard of care.
Study: NCT02407288

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Study: NCT02325492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound
Study: NCT02491645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory interventions
Description: 1. Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~2. Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~3. Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~4. Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~5. Auditory stimulation : Sound familiarisation and music time will be done.
Study: NCT02192645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfujiu
Study: NCT03308799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 cream
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cal/BDP combination
Description: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: Vehicle Cream
Study: NCT00969111

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
Description: Postop High Risk

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton (prostate bed) to 70.2 CGE
Description: Salvage Non-High Risk

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
Description: Salvage High Risk

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton to 66.6 CGE
Description: Post-Op Non High Risk
Study: NCT03473184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein 1% ointment
Description: Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
Study: NCT03517501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART-123
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study: NCT02688985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as IV infusion.
Study: NCT03517501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator - Placebo
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study: NCT02688985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as IV infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyloprednisolone
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyloprednisolone
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyloprednisolone
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyloprednisolone
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
Study: NCT02577237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person education sessions
Description: The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Booklet
Description: Radiation Oncology Nurse will hand participant the NCI booklet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
Study: NCT00066066

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
Study: NCT02268409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection
Study: NCT02245542

Intervention type: DRUG
Intervention: ALNA®OCAS®
Study: NCT02805335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTFIX PLUS
Study: NCT04538066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryostatin 1
Description: Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
Study: NCT02155738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV normal saline
Study: NCT03324763

Intervention type: OTHER
Intervention: stool sampling
Description: A stool sample will be collected to perform the H. pylori antigen test
Study: NCT01918527

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Orally on days 1-14: 2000 mg/m2/day q3w

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Orally on days 1-14: 2000 mg/m2/day q3w

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Intravenously on day 1: 130 mg/m2 q3w

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Intravenously on day 1: 130 mg/m2 q3w
Study: NCT04122859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Skin Closure Device
Description: The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Skin Closure Device
Description: The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
Study: NCT00542919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily until progressive disease
Study: NCT04428892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedagogyc Strategy
Description: Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedagogyc Strategy
Description: Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
Study: NCT02688985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyloprednisolone
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.